Clinical Trial Goal
To find out if the combination of LP-168 and obinutuzumab is safe and works well to treat CLL or SLL
You may be able to join this trial if you:
- Are 18 years old or older
- Have CLL or SLL
- Have been treated with one of the following (your doctor can tell you this):
- BCL2 inhibitor
- BTK inhibitor
- Do not have Richter's transformation
- Have not had allogeneic (cells from a donor) or autologous (your own cells) blood or marrow transplant (BMT) in the last 2 months
- Do not have graft-versus-host-disease (GVHD)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
LP-168 is a small molecule inhibitor that blocks BTK on certain cells.
Obinutuzumab is a monoclonal antibody that targets CD20 on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Obinutuzumab is a monoclonal antibody that targets CD20 on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- LP-168 – A pill that you take by mouth 1 time each day
- Obinutuzumab – Given as intravenous (IV) infusions up to 4 times
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for 6 years.
The Food and Drug Administration (FDA) has not yet approved LP-168.
Locations
University of Cincinnati Medical CenterRECRUITING
Cincinnati, Ohio
Contacts:
- UCCC CTO, 513-584-7698, cancer@uchealth.com
- Christine Vollmer, mccordce@ucmail.uc.edu
Sponsors
collaborator: Newave Pharmaceutical Inc, lead: Zulfa Omer
